ArticleJournal of gastroenterology2010
Adiponectin receptors are downregulated in human gastric cancer.
Article in Journal of gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 28 citations in OpenAlex.
- AdipoR2 inhibits human glioblastoma cell growth through the AMPK/mTOR pathway.European journal of medical research · 2021Article
- Association of variants on ADIPOQ and AdipoR1 and the prognosis of gastric cancer patients after gastrectomy treatment.Molecular biology reports · 2015Article
- Adiponectin receptor expression predicts favorable prognosis in cases of hepatocellular carcinoma.Pathology oncology research : POR · 2014Article
- microRNA-423-3p promotes tumor progression via modulation of AdipoR2 in laryngeal carcinoma.International journal of clinical and experimental pathology · 2014Article
- Adiponectin receptor expression in gastric carcinoma: implications in tumor development and progression.Journal of cancer research and clinical oncology · 2013Article
- Genetic analysis of ADIPOQ variants and gastric cancer risk: a hospital-based case-control study in China.Medical oncology (Northwood, London, England) · 2013Article
- Role of adiponectin and its receptors in cancer.Cancer biology & medicine · 2012Article
- Adiponectin receptor 2 is negatively associated with lymph node metastasis of colorectal cancer.Oncology letters · 2012Article
- Adiponectin receptor-1 expression is associated with good prognosis in gastric cancer.Journal of experimental & clinical cancer research : CR · 2011Article
- Excess body weight and obesity--the link with gastrointestinal and hepatobiliary cancer.Nature reviews. Gastroenterology & hepatology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdiponectin has been shown to have suppressive effects on tumor development, but the expression of adiponectin receptors in tumor tissue has not been fully elucidated. The purpose of this study was to quantitatively evaluate the expression of two adiponectin receptors, AdipoR1 and AdipoR2, in gastric cancer tissue.
methodsThe mRNA levels of AdipoR1 and AdipoR2 were evaluated by quantitative reverse transcription polymerase chain reaction (RT-PCR) and immunohistochemical staining in 67 gastric cancer tissues and their normal counterparts. In addition, the effects of cytokines on AdipoR1 and AdipoR2 expression in cultured gastric cancer cells were examined.
resultsAs compared to findings in the normal counterparts, AdipoR1 mRNA expression, standardized by β-actin mRNA, tended to be lower (cancer 0.488 ± 0.039, normal 0.955 ± 0.281, p = 0.0726) and AdipoR2 expression was significantly lower (0.818 ± 0.081, 1.500 ± 0.222, p = 0.0035) in gastric cancer tissue. Immunohistochemical examination showed the same tendency for AdipoR1 and AdipoR2 expression in epithelial cells. Moreover, AdipoR2 was strongly expressed in interstitial cells. However, the expression levels of these receptors did not show a strong correlation with various pathological factors. An in vitro experiment using two gastric cancer cell lines, MKN-74 and NUGC-3, showed that the expression levels of AdipoR1 and AdipoR2 were significantly decreased by transforming growth factor (TGF)-β in a dose-dependent manner.
conclusionsTwo major adiponectin receptors were decreased in gastric cancer as compared to findings in normal gastric epithelium. TGF-β may be involved in this receptor downregulation. This downregulation may be an ideal strategy for cancer cells to escape the antiproliferative effects of adiponectin in the initial phase of tumor development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.